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Abstract Sera from HIV-l infected individuals were examined for their reactivity to the principal neutralizing domain, IGPGRAF sequence, of the 
V3-loop of HIV-l. Four hybrid proteins carrying this sequence inserted in four different outer loops of a protein that makes up the capsid of an 
insect virus were used as antigen in a Western blot assay for this survey. All the four antigens howed different activity: sera that recognise all antigens 
to sera that reacted with only one of them. Competition experiments indicated that the antibodies recognised these proteins with different atlinity. 
Molecular modelling of the hybrid proteins predicted that the inserted sequence adopted different conformations in each position. Comparison of 
predicted most stable conformations for IGPGRAF indicated that there is a close relationship between conformational similarity to a V3-loop 
reference structure and the degree of reactivity with sera. 
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1. In~oduction 
The V3 domain of the HIV-I glycoprotein (gp120) is a strong 
immunodominant epitope capable of inducing an antibody re- 
sponse in at least 90% of the sera of patients infected with HIV 
[ 11. It is the single most important epitope, defined to date, that 
can invoke a neutralizing response in vaccinated animals or 
humans [2-91. However, as it is a very variable domain, it 
induces a type-specific immune response. LaRosa et al. [lo] 
found that the amino acid sequence at the tip of the V3-loop, 
GPGR, is far more conserved than the rest of the sequence. 
This is probably due to the structural constraints imposed by 
gp120 functionality. It was subsequently demonstrated that 
human monoclonal antibodies directed against this conserved 
sequence xhibit a rather broad neutralisation range [ 11,121. It 
has also been reported that a single amino acid substitution in 
this sequence can completely alter its conformation and prevent 
the attachment of neutralizing monoclonal antibodies [13]. 
Until now, the evaluation of anti-V3 antibodies has been mostly 
made using peptides containing the core sequence as well as the 
flanking regions, which make it difficult to discriminate the 
origin of the immunoresponse. Furthermore, free peptides can 
adopt a wide set of low energy conformations, except in the 
simpler antibody response to a linear sequence, and hence they 
are of low value for the discrimination of the type of humoral 
response. We have developed a new epitope-presenting system 
based on the capsid protein of the insect virus Flock house virus 
(FHV). This protein scaffold was used as a carrier for an HIV-l 
V3-loop epitope. The X-ray structure of this FHV protein is 
known at 2.8 A resolution [14], and this allows the choice of 
the positions where the foreign HIV sequence will be located. 
Fig. 1 shows a ribbon diagram of the 3D structure of the FHV 
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capsid precursor protein. The sites chosen for insertion (Ll, L2, 
L3, 13) are indicated at the outer loops of the protein which 
connect /?-sheets of the eight stranded B-barrel structure. In this 
way the inserts are placed on the exterior surface of the protein. 
These antigens were extremely useful in studying the influence 
of the stereochemistry of the presenting molecule in the recog- 
nition of a short heterologous amino acid sequence by the 
human immune system. Our results demonstrate how the reac- 
tivity of a foreign sequence, in this case IGPGRAF of HIV 1, 
is affected by its location in the carrier protein. Molecular 
modelling studies indicated that different environments impose 
different conformations on the core sequence IGPGRAF. 
There was a good correlation between the similarity of the 
modelled structure of each conformer and those of the V3-loop 
reference structure and their corresponding reactivity with 
HIV- 1 -positive sera. 
2. Material and methods 
2.1. Plasmid construction and protein expression 
The construction of the plasmids carrying the FHV capsid precursor 
and the genetic manipulation performed to produce the hybrid genes 
(carrying the IGPGRAF sequence) used will be described in detail 
elsewhere (Scodeller et al., unpublished). Briefly, the RNA2 of FHV 
was mutagenixed to create the sites Ll, L2, L3,13, and to introduce the 
foreign sequence IGPGRAF of HIV1 (Fig. 1). BL21(DE3) E. coli 
carrying a chromosomal copy of the phage T7 polymerase gene under 
the control of the inducible lacUV5 promoter was used as host for 
expression of hybrid proteins from PET vectors (Novagen, Madison, 
WI). Expression and purification of recombinant proteins were per- 
formed as described [15]. 
2.2. Immunoassay 
To evaluate the reactivity of the expressed proteins with sera from 
HIV-l-positive individuals or anti-FHV rabbit sera, the proteins were 
transferred to nitrocellulose membranes as described [16]. Protein 
bands on the membrane were identified by Ponceau red staining and 
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subsequently narrow strips containing the bands, corresponding to the 
hybrid antigens or the wild-type FHV protein, were cut out. The strips 
were blocked for 1 h in 5% (w/v) non-fat dry milk in PBS and then 
incubated for 24 h with the different sera, diluted in PBS-0.5% Tween 
20 (1: 100 dilutions of human sera and 1: 2000 dilutions of rabbit anti- 
FHV serum). Bound antibodies were detected by incubation of the 
strips with either horseradish peroxidase-conjugated anti-human or 
anti-rabbit antibody, and developed with hydrogen peroxide-3’-3- 
diaminobenzidine tetrahydrochloride. 
2.3. Patient sera 
Sera from HIV-l-infected individuals were obtained from Cattinara 
Hosoital. USL No. 1. Trieste. Italv. The sera were classified as nositive, 
based on a twice-repeated reac&ity in an ELISA test assay (Abbott 
Recombinant HIVl-2, 3rd Generation EIA-Abbott) and confirmed 
with Western blot (New Lav Blot l-Diagnostics Pasteur). All the sera 
were also tested by Abbott Envacor HIV 1 EIA-Abbott and all were 
found to be positive. 
ELISAs were performed as previously described [2] using 20 amino 
acid synthetic peptides representative of the principal neutralizing do- 
main (PND) of HIV-l strains MN, SF2 and SC, obtained from Amer- 
ican Bio-Technologies Inc. (Cambridge, MA). 
2.4. Molecular modelling 
The evaluation of the total energy of the calculated molecular sys- 
tems was performed by the method of molecular mechanics with cvff 
(consistent valence force field) [18] of the Insight II package (Biosym 
Technologies) [18]. The total energy was considered as the sum of 
bonding terms (r, j, q) and non-bonding terms (dispersion, repulsion 
and electrostatics). The geometries of individual structures were op- 
timised using a conjugate gradient method [19] starting from different 
initial geometries and searching for absolute minima of energy. The 
starting geometry of the FHV capsomer protein, for computer mod- 
elling, was created from X-ray coordinates of BBV capsomer protein 
[20]. As the primary structures of the FHV and BBV capsomer proteins 
are highly homologous [21], differing residues in the structure of BBV 
have been replaced to fit the FHV sequence. The whole structure of the 
protein was then optimised by molecular mechanics, thus obtaining a 
reference geometry for the FHV capsomer protein (Fig. 1). This was 
the base for the modelling of structural modifications introduced by the 
insertion of IGPGRAF at the sites Ll, L2, L3 and 13. 
3. Results and discussion 
The HIV sequence to be inserted in the FHV capsomer pro- 
tein was IGPGRAF, which represents amino acid 314-320 
within the HIV-l V3-loop of the strains MN, SC and SF2. 
According to extensive sequence analysis studies, this sequence 
is present in 52% of the circulating strains in the United States 
and Europe [10,22]. The insertion of this sequence in sites Ll, 
L2 and L3, resulted in the deletion of 4 or 5 amino acids of the 
original FHV sequence, concurrently with the insertion of the 
HIV sequence. In the case of position 13, the HIV sequence was 
inserted without any deletions in the FHV sequence. However, 
the genetic handling to introduce the new sequence stretch 
created an extra glutamic acid at the carboxy-terminus of the 
insertion (Fig. 1). Fig. 2A shows the Coomassie blue staining 
of a gel of the FHV capsid protein and the hybrids derived from 
it which carry the sequence IGPGRAF. As expected, all of the 
proteins reacted with anti-FHV-specific rabbit antiserum. The 
same samples, blotted onto nitrocellulose, were probed with 
sera from 50 HIV-l-infected patients. 62% of the HIV-l-posi- 
tive sera analysed recognized at least one of the hybrid protein 
antigens and failed to react with the wild-ype FHV capsid 
protein without any HIV insert. Five characteristic patterns of 
reactivity were obtained (Fig. 2B): (i) all four hybrids were 
reactive (22.6%), (ii) L2, L3, I3 reactive (3.2%), (iii) Ll, L2 and 
L3 reactive (9.7%) (iv) L2, L3 reactive (3.2%), and (v) only L2 
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(61.7%). The total number of sera that reacted with one or more 
of the hybrid proteins is in agreement with the known number 
of patients infected with HIV-l strains that carry the 
IGPGRAF sequence [lo]. When tested by ELISA against syn- 
thetic peptides carrying sequences representative of several 
HIV-l strains (MN, SF2 and SC), 90% of the sera gave positive 
results. This result is in complete agreement with those of other 
labs [l]. Instead, reactivity against IGPGRAF might be more 
stringent because of the restraint imposed on the sequence by 
the structure of the FHV capsid protein. It should also be 
considered that with antigens carrying the IGPGRAF se- 
quence, antibodies directed against the flanking region of this 
sequence are not detected. 
L2 seems to be the most reactive hybrid since it is recognized 
by all positive sera. Instead, Ll and L3 are recognized by only 
32% of the patients. 13 is the less reactive hybrid (17%). These 
results could be explained by a hierarchical order of recognition 
based on the differential affinity of human antibodies for re- 
lated but not identical antigens. Another possibility is that the 
sera of HIV-l infected patients contain several different anti- 
bodies which bind selectively only to some of the hybrid anti- 
gens. If the different recognition is based on a different affiity 
for the antigens, then these proteins should compete for the 
specific antibodies present in the sera. That this is the case is 
demonstrated by the results in Fig. 2C which show the reactiv- 
Positions aa deleted aa insertion 
Ll 205-209 (5) IGPGRAF 
L2 268-272 (5) IGPGRAF 
L3 131-134 (4) IGPGRAF 
13 303 (0) IGPGRAFE 
Fig. 1. 3D ribbon structure of FHV capsomer protein showing the 
positions of Ll, L2, L3 and I3 sites chosen for the insertion of 
IGPGRAF sequence. Amino acid position in FHV and the modifica- 
tions done for inserting the HIV-l sequence in the different sites. 
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Fig. 2. Reactivity of the hybrid proteins (FHV-IGPGRAF) transferred 
to nitrocellulose to (A) anti-FHV. (B) HIV-I positive patients. 
(C) Serum 45 in the presence or absence of L2 protein. 
ity of serum 45 in the presence or absence of L2 protein. When 
L2 is present, it captures all the reactive antibodies, instead 
when it is absent, Ll and L3 become positive. This would 
indicate that although Ll and L3 are able to bind specific 
antibodies present in the serum, they can not compete for 
binding when L2 is present. This is in agreement with the fact 
that L2 is the most reactive antigen, followed by Ll and L3 
(with similar reactivity), and 13 (the least reactive). Sera with 
the highest titers of anti-IGPGRAF have enough antibodies to 
detect even antigens of low affinity, like 13, but when the titer 
of these specific antibodies is low the reactivity is restricted to 
more suitable antigens, like Ll and L3 or only to L2. 
The different conformations that the HIV-specific sequence 
can adopt in each position of the FHV capsid protein can 
present different affinities. To test this hypothesis, the possible 
structures that the sequence IGPGRAF may adopt in the dif- 
ferent positions of the protein carrier were calculated by molec- 
ular mechanics preceded by short molecular dynamic runs. The 
most stable conformers inserted in the FHV capsid protein at 
the sites Ll, L2, L3 or 13 are shown in Fig. 3. From the many 
different conformations obtained for the protein structure with 
IGPGRAF at each of the positions, those with the lowest en- 
ergy (most stable) were selected. In all four cases, it was found 
that the structure of the protein is affected mostly in regions 
adjacent y the inserted IGPGRAE segment (around 10 resi- 
dues on both sides); Aiart from the region of insertion, the 
dverall changes of the hybtidprotein are npt sign&ant. As to 
the IGPGRAF &nent itself, its cooformation varies signifi- 
cantly accord&g tp the sites of insertion (Fig: j). There are 
differences in tile backbone orientation of the &rnent. In Ll 
and 13 the inserted segments present a sharp tti at P-G resi- 
dues. L2 and L3 show two turns. It can be assumed that the 
structure which best resembles the conform&m of IGPGRAF 
within gp120 would be the most reactive with HIV antibodies. 
Since the X-ray structure of whole ~120 has not yet been 
determined, a direct comparison it4 not possible with the pre- 
dicted structures hown in Fig. 3. However, the X-ray structure 
of a complex between a segment of the V3-loop peptide con- 
taining the sequence 4GPGRAF and an HIV- l-neutralizing Ab 
was recently published 1231 and &II @e used for comparison. In 
this complex, the V34oop segment has an S-shaped conforma- 
tion with two turns at P-G and R-A. The sin$l&ity,between this 
structure and the structtire of IGPGaF at L2 or L3 is higher 
than when IGPGRAF is at. L1 or. e. The’similarity, clearly 
show by the ribbons in Fig. f&an be ciuantified I$ RMS (root 
mean squares) of the differences of thecorr@oiiding coordi- 
natis of all atoms, taking the V3 portion oftbir structure (of 
the peptidsantibody complex) as a refereq&. The following 
order of,s~ilarity between IGPGRAF in@i&d iriFHV and the 
reference structure was thus obtained: 
Positions: L2 > Ll > L3 2 13 
RMS: 2.12 2.67 3.01 3.15 
The orientation of the side chains is in all cases somewhat 
different, probably due to alterations conferred by the antibody 
to the V3 structure and possible flexibilities of the individual 
insertions. Nevertheless, there is a clear correlation between the 
predicted similarity of our constructs to a putative V3 reference 
structure and their reactivity with HIV-l-specific antibodies. 
In the present studies we analysed proteins previously dena- 
tured as required by the SDS-PAGE technique. It can be ar- 
gued that the protein structure is changed and therefore any 
conclusions about reactivity and conformation are too specula- 
tive. However, it has been demonstrated that activity can be 
regained, after SDS-PAGE, for a number of enzymes and 
DNA-binding proteins [24--261. This would not be possible 
without the partial or full renaturation of these proteins to their 
original native states. A similar process of renaturation after 
electrophoresis could account for our findings. 
Knowledge of the 3D structure of the FHV capsid protein 
allows the possibility of inserting epitope sequences in different 
outer regions of the carrier protein. Our results demonstrate the 
influence of the surrounding structure on the reactivity of for- 
eign sequences introduced in carrier proteins with specific anti- 
bodies. The predicted most stable conformations for 
IGPGRAF indicated that there is a close relationship between 
conformational similarity to a V34oop reference structure and 
the degree of reactivity with sera when this sequence is properly 
located in the FHV carrier protein. 
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Fig. 3. ComDarison between HIV-l IGPGRAF seauence conformation and the most stable structures of IGPGRAF inserted in sites Ll, L2, L3 
13% the FHV capsomer protein. 
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